The three years since our last conference in San Francisco have again seen a dramatic expansion of the number of antivirals either licensed or in the late stages of clinical trials. d4T is now licensed for HIV infection, famciclovir and the oral pro-drug of acyclovir, valacyclovir, are now licensed for VZV infections in some countries. Moreover. oral ganciclovir, cidofovir, and sorivudine are not far behind. Clinical trials with the second-site reverse transcriptase inhibitors and the protease inhibitors for HlV infection are proceeding rapidly and on a broad scale, and the preliminary...

Scientists and clinicians attending the last "New Directions in Antiviral Therapy" conference in late 1994 could hardly have predicted the revolution in the management of patients with HIV infection that has occurred since. Two new classes of antiretrovirals have been licensed, the second-site RT inhibitors and the protease inhibitors; the long in- cubation period of active HIV infection, when the infection is clinically latent, is now un- derstood to be a period of intense viral replication and turnover of CD4 lymphocytes; measurements of HI V RNA concentration in plasma have been shown to...

Europe's Economic Dilemma analyses the reasons why the European Union's growth rate has fallen during the last quarter of a century to little more than a third of its previous level. It concludes that the major reason has been politically driven attempts to lock EU currencies together in inappropriate economic circumstances. These have led to chronic deflation, rising unemployment and falling investment and competitiveness as EU Member States, without exchange rate flexibility, have found themselves unable to compete with Germany.

Europe's Economic Dilemma analyses the reasons why the European Union's growth rate has fallen during the last quarter of a century to little more than a third of its previous level. It concludes that the major reason has been politically driven attempts to lock EU currencies together in inappropriate economic circumstances. These have led to chronic deflation, rising unemployment and falling investment and competitiveness as EU Member States, without exchange rate flexibility, have found themselves unable to compete with Germany.

America's Soluble Problems, while recognising the many successes of the US economy, analyses its well known problems with a fresh new approach. Are slow growth, stagnant living standards for many, increasing poverty for those worst off, the hollowing out of much US manufacturing, balance of payments and fiscal deficits, all inevitable? America's Soluble Problems argues that they are not, and that entirely achievable changes in macro - economic policy could transform the prospects for the US economy and for most American citizens.

This scarce antiquarian book is a facsimile reprint of the original. Due to its age, it may contain imperfections such as marks, notations, marginalia and flawed pages. Because we believe this work is culturally important, we have made it available as part of our commitment for protecting, preserving, and promoting the world's literature in affordable, high quality, modern editions that are true to the original work.

The three years since our last conference in San Francisco have again seen a dramatic expansion of the number of antivirals either licensed or in the late stages of clinical trials. d4T is now licensed for HIV infection, famciclovir and the oral pro-drug of acyclovir, valacyclovir, are now licensed for VZV infections in some countries. Moreover. oral ganciclovir, cidofovir, and sorivudine are not far behind. Clinical trials with the second-site reverse transcriptase inhibitors and the protease inhibitors for HlV infection are proceeding rapidly and on a broad scale, and the preliminary...